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Abstract
Urinary tract infections (UTI), associated with vesicoureteral reflux (VUR), can lead to chronic kidney disease. Genetic
alterations in the innate immune defenses contribute to UTI risk. We investigated a novel gene, Dachsous Cadherin-
Related 1 (DCHS1), in children with UTI. We determined absolute DNA copy number (CN) of DCHS1 in children with
UTI. In this case-control study, we utilized multiple complementary methods to determine the genomic CN of DCHS1.
Children with (n¼ 370) and without (n¼ 71) VUR from two well-phenotyped clinical trials of UTI were copy-typed and
compared to 491 healthy controls with no known history of VUR or UTI. Less than 1% of controls had a single copy of
DCHS1, while 31% of children with UTI and no VUR and 7% of children with UTI and VUR had a single copy of the
DCHS1 gene. Using immunostaining, we localized expression postnatally to the bladder and renal epithelia. Mice were
also challenged with two uropathogenic Escherichia coli strains, and Dchs1 mRNA was quantified. This study represents
the first report of DCHS1 in association with pediatric UTI. We hypothesize that its role in innate immunity is critical to
lower urinary tract defense. Further investigation is required to determine the role of DCHS1 in innate immunity.
Keywords
DNA CN variations, pediatrics, urinary tract infections, vesicoureteral reflux
Date Received: 21 January 2020; revised: 10 March 2020; accepted: 15 March 2020
Introduction
Urinary tract infection (UTI) is one of the most
common childhood infections and is caused by uropa-
thogenic Escherichia coli (UPEC) in 80% of cases.1
Acute pyelonephritis has variable sequelae with or
without renal scars, depending on the virulence of the
organism and host defense mechanisms.2,3 Children
with congenital anomalies of the kidney and urinary
tract, such as vesicoureteral reflux (VUR), are at
increased risk for UTI-associated sequelae such as
chronic kidney disease and renal scarring.4
The innate immune system plays a critical role in
protecting the urinary tract from uropathogens.5,6
Innate immune responses are rapid and encompass a
variety of components, including epithelial extracellu-
lar barriers and intracellular tight junctions, antimicro-
bial peptides, PRRs, inflammatory mediators, and
phagocytes.6–8 PRRs are protein receptors on the
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surface of phagocytes, dendrites, and epithelial cells,
which recognize microbial molecules and are capable
of initialing immune responses called PAMPs.9
A number of studies implicate a heritable compo-
nent to UTI susceptibility.10,11 A potential mechanism
for UTI heritability is genetic alterations in innate
immune defenses.12 For example, DNA copy number
(CN) variations (CNVs) in the gene that encodes
a-defensin 1 have been shown to be associated with
variable susceptibility to UTIs and response to antibi-
otic prophylaxis.13 CNVs occur when DNA sections
between a few hundred and several million bp are delet-
ed or duplicated and influence disease by a range of
mechanisms, including gene dosage.14,15 We performed
high-resolution genome-wide array comparative geno-
mic hybridization (aCGH) comparing children with
VUR and UTI to healthy controls. We identified a rel-
ative CNV in the gene Dachsous Cadherin-Related 1
(DCHS1) that segregated to patients with VUR.16 A
limitation of aCGH is that it only determines if DNA
CN is relatively increased or decreased compared to a
reference sample and does not define the absolute
number of gene copies that are present.13,16 Thus, val-
idation methods to determine true CNs are needed to
rule out false-positives.13
DCHS1 encodes for a calcium-dependent adhesion
molecule, which has a role in kidney development and
planar cell polarity.16,18 The gene has not been previ-
ously investigated in the context of UTI. The purposes
of this study were to determine absolute DCHS1 CN in
two pediatric clinical trial cohorts of UTI and to inves-
tigate its postnatal role in innate immune defenses.
Methods
Safety approval of human subjects
Approval of human subjects was obtained through the
University of Tennessee Health Science Center
Institutional Review Board Protocol 14-03325-XP.
All clinical investigations were conducted according
to the principles expressed in the Declaration of
Helsinki.
Cohorts
We utilized genetic samples from three clinical cohorts
of children and adults with and without a history of
UTI. All genomic DNA samples were obtained from
immortalized lymphoblastic cell lines. Each is described
below.
Cohort of subjects with VUR and UTI
The Randomized Intervention for Children with
Vesicoureteral Reflux (RIVUR) Clinical Trial
(ClinicalTrial.gov Identifier NCT00405704) enrolled
patients aged 2–71 mo with one to two UTI who
were diagnosed with grade 1–4 VUR.19 Patients were
randomized to receive antibiotic prophylaxis or place-
bo and were followed for 2 yr for recurrent UTI. UTI
was defined as a positive culture with a single organism
of 50,000 CFU/ml on a catheter specimen or 100,000
CFU/ml on a clean catch specimen with evidence of
pyuria on the urinalysis, as per guidelines by
American Academy of Pediatrics (AAP) at the time
of collection.20 We utilized DNA obtained from 320
non-Hispanic Caucasian girls from the RIVUR study.
Cohort of subjects with UTI without evidence of VUR
The Careful Urinary Tract Infection Evaluation
(CUTIE) Study observed 2–71 mo old pediatric
patients who had one to two UTI without VUR for a
2 yr period.21 The CUTIE Study was concomitant with
the RIVUR study. We utilized 71 DNA samples
from non-Hispanic Caucasian girls enrolled in the
CUTIE Study.
Control cohort without VUR and UTI
We utilized 491 DNA samples of healthy, non-
Hispanic Caucasian adult women with no known his-
tory of VUR and UTI.
Mice
In vivo murine studies were approved by Indiana
University Institutional Animal Care and Use
Committee (IACUC) under protocol # 11333. Wild-
type C57BL/6J female mice (Jackson Laboratory, Bar
Harbor, ME) were used for induction of pyelonephritis
and cystitis in infection studies.
Absolute CN determination
Absolute CNs of DCHS1 were determined by digital
PCR (dPCR) and were confirmed with Short Multiply
Aggregated Sequence Homologies (SMASH) methods
for seven reference individuals who were used on each
plate as calibrators for relative quantitation for quan-
titative RT-PCR (qRT-PCR).
dPCR
To determine absolute DCHS1 CN, quantitative dPCR
was performed on seven reference individuals at the
Molecular Resource Center at the University of
Tennessee Health Science Center on a Fluidigm
BioMark System (San Francisco, CA). For complete
methodology, please refer to the manufacturer’s proto-
col (Fluidigm PN 100-6896 B1). Briefly, we used dPCR
37 K integrated fluidic circuits (IFC). After filling IFC
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with standard control line fluid, we primed the IFC in
Fluidigm MX. A pre-mix sample mixture, which
included TaqMan gene expression master mix
(Applied Biosystems, Foster City, CA), 20 GE
Sample Loading Reagent, and TaqMan copy-typing
primer/probe mixtures (Applied Biosystems), was used.
Specifically, RNASEP VIC-labeled probes were
used as an internal reference for diploid genes and
DCHS1-FAM labeled probes for our target gene
(Applied Biosystems). We added 1.8 ml sample DNA
(20 ng/ml) to 4.2 ml above mixture in each pre-mix well.
After priming, IFC 37 K was loaded with 4.0 ml from
each sample. Each sample was genotyped in triplicate.
The data were analyzed with Fluidigm Digital PCR
Analysis Software v4.1.2.
SMASH
We performed a next-generation sequencing-based
method for CNV analysis by SMASH, as previously
described.22
qRT-PCR
Multiplex qRT-PCR was performed on all subjects and
controls to determine the relative CN of the DCHS1
gene, as previously described.13 Briefly, individuals
with known CNs from dPCR and SMASH sequencing
served as calibrators to determine CN for unknown
samples using a standard curve for DDCt. TaqMan
copy-typing primer/probe mixtures (Applied
Biosystems) were used. RNASEP-VIC-labeled probes
were used as an internal reference for diploid gene,
and DCHS1-FAM labeled probes for the target gene.
Each sample was performed in triplicate. Experiments
were performed on a Light Cycler 480 (Roche, Basel,
Switzerland) Real-Time PCR System. Primers/
probe sequences were as follows: DCHS1_F 50-CGG
TAA GGC AGG TTG GTG-30; Probe
FAM-AGGTGCTGATGTGGAGTGTTGGGG-MB
G; and DCHS1_R 50-AGT TAG GTC TGG GAG
TGA GG-30.
The comparative cycle threshold (Ct) difference
method was used to determine the CN for the
DCHS1 gene for each patient.23 This was done using
LCS480 v1.5.1.62 software and Microsoft Excel 2010.
The method measured the DCt by subtracting the aver-
age Ct of DCHS1 as the target and the average Ct
RNASEP as the reference and then calculating the
DDCt value by comparing the average DCt values of
samples with the average DCt of the calibrator sample
known to have two copies of the target sequence.24
Known calibrators with two CNs of DCHS1 gene per
diploid genome as determined by dPCR and SMASH
were included on each plate to create a standard curve
for CN in unknown. The amount of target normalized
to endogenous reference and relative to calibrator is
calculated by 2–DDCt.
Immunofluorescence staining
Paraffin embedded human kidney and bladder sections
(7 lm thick) were stained with polyclonal rabbit anti-
DCHS1 Ab (cat. no. Ab203690; Abcam, Cambridge,
MA) to locate DCSH1-positive cells in the kidney and
bladder and V-ATPase E1 (cat. no. GW22284F;
Sigma–Aldrich, St. Louis, MO) in conjunction with
DCHS1 to locate intercalated cells positive for
DCHS1 in the kidney. Human kidney samples with
and without pyelonephritis were obtained from the
Cooperative Human Tissue Network (Westerville,
OH), as previously described.25 DCHS1 primary Ab
was added at a 1:50 dilution, and V-ATPase E1 was
added at 1:300 dilution and incubated overnight at
4C. To visualize, DCHS1 and anti-Rabbit Cy3
(1:600 final dilution) secondary Ab and to locate inter-
calated cells, anti-Chicken AF488 (1:600 final dilution)
was used (Jackson ImmunoResearch, West Grove, PA)
for 30 min at 20C. Slides were mounted using DAPI
containing a hard-set solution to visualize nuclear
staining (Vector Laboratories, Burlingame, CA).
Sections were visualized using a Keyence BZ9000
microscope (Keyence Corporation, Osaka, Japan).
Murine bacterial challenge experiments
To determine the mRNA in mouse models with UTI
compared to control, E. coli pyelonephritis stain
(UPEC; CFT073) and cystitis strain (UPEC; UTI89)
were grown overnight on Luria-Bertani (LB) media at
37C in a 20xg shaker and static incubator, respective-
ly. OD600 measurements were recorded using the
Eppendorf Biophotometer Spectrophotometer UV/Vis
Reader (Eppendorf North America, Hauppauge, NY)
to adjust the bacterial inoculum concentration to
1 108CFU/ml per mouse. Bacterial cultures were
made into two 1ml aliquots and centrifuged at
5,500 g for 1 min. Supernatant was discarded without
disturbing the pellet. Sterile PBS (1 ml) was then added
to each tube. Tubes were vortexed several times in
order to suspend the bacteria pellet in sterile PBS.
The goal optical density of the bacterial solution was
0.073 OD600, which correlated to a concentration of
1 108 CFU/ml. Specifically, a mixture of 800 ml sterile
PBS and 20 ml bacterial solution were combined and
placed in a cuvette to be measured in the OD600 reader.
From this baseline measurement, the bacterial/PBS
suspension was added from the stock in 20 ml incre-
ments until an OD600 of 0.073 was reached. The mice
were anesthetized with 2.5% isoflurane and then placed
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in the supine position. Bladders were palpated, and
urine was expelled before transurethral inoculation
was performed. Then, a sterile 1 cc syringe (Becton
Dickinson, Franklin Lakes, NJ) with lubricated
polyethylene-coated needle (Becton Dickinson,
Franklin Lakes, NJ) was used to administer 50 ml of
bacterial suspension transurethrally. The same volume
amount of sterile PBS was inoculated transurethrally as
a negative control. Mice were euthanized 6 h after inoc-
ulation of bacteria by CO2 inhalation for organ
harvesting.
mRNA extraction and quantification
For quantifying the mRNA in mice, murine kidneys
and bladders were placed into zirconium bead/PBS
vials for homogenization in the Bullet Blender Storm
24 (Next Advance, Troy, NY) for 10 min at maximum
speed. Following tissue homogenization, mRNA was
extracted using an RNeasy Plus Mini Kit (Qiagen,
Valencia, CA) and reverse transcribed using a High
Capacity cDNA Reverse Transcription Kit (Applied
Biosystems) as per the manufacturer’s protocol. qRT-
PCR was performed using gene expression Dchs1 pri-
mers (Sigma–Aldrich) and Gapdh (Real Time Primers,
LLC, Elkins Park, PA) as the housekeeping gene
primer. The forward and reverse primer sequences for
Dchs1 were 50-CTATACACCCTAACTGGTCC-30
and 50-AGAGTTAGTACATAGTGAGGC-30, respec-
tively. QuantiFast SYBR Green real-time PCR
Mastermix (Qiagen) was used for qRT-PCR assays
on the CFX Connect 96 well real-time system (Bio-
Rad Laboratories, Hercules, CA). Dchs1 mRNA
expression was quantified using the 2–DDCt method
and normalized values to the gene expression of Gapdh.
Statistical analyses
In genetics, the results were analyzed using SAS v9.4
(SAS Institute, Cary, NC). Categorical variables were
compared using the chi-square test or Fisher’s exact
test, depending upon the variable number in the box.
The level of significance was defined as a P value
of < 0.05. In mRNA comparisons, normalized
Dchs1 mRNA expression data are presented as the
meanSD. Statistical analysis by unpaired two-tailed
t-test was used to compare the response between UPEC
to saline control groups and plotted in GraphPad
Prism 8 (GraphPad Software, La Jolla, CA). A
P value of < 0.05 was considered statistically significant.
Results
Subject and control cohort characteristics
We determined DCHS1 gene CN per diploid genome
using qRT-PCR in RIVUR (UTI and VUR; n¼ 320)
subjects, CUTIE (UTI and no VUR; n¼ 71) subjects
and controls (no UTI and no VUR; n¼ 491). All
cohorts comprised non-Hispanic Caucasian females.
The clinical characteristics of the groups are given in
Table 1.
Children with VUR and UTI had decreased CN
of DCHS1 compared to controls
DCHS1 CN in children with RIVUR varied from 1 to
3, with a mean CN of 1.95 0.30. DCHS1 CN for
controls ranged between 1 and 4, with a mean CN
of 2.49 0.39. The distribution of CNs is shown in
Figure 1. More RIVUR subjects (n¼ 23; 7%) had
one copy of DCHS1 compared to controls (n¼ 3;
0.6%). In the RIVUR cohort, one copy individuals
were 13 times more prevalent (odds ratio (OR)¼
12.59; 95% confidence interval (CI) 3.75–42.32;
Table 1. Clinical characteristics of subjects and controls.
RIVUR, n¼ 20 CUTIE, n¼ 71 Control, n¼ 491
Disease profile UTIþVUR UTI No UTI and no VUR
Mean age, mo (range) 22.7 (2–71) 22.7 (2–71) >18 yr






































Figure 1. DCHS1 DNA copy number (CN) in subjects with UTI
without vesicoureteral reflux (VUR), UTI with VUR, and con-
trols. DCHS1 CN distribution and percentages in subjects with
UTI without VUR (n¼ 71), UTI with VUR (n¼ 320), and controls
(n¼ 491).
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P< 0.0001). Distribution of 1 versus  2 CNs in groups
is given in Figure 2.
Children with UTI and without VUR had a higher
incidence of low DNA CN of DCHS1 compared
to controls, as well as children with VUR
The DCHS1 CN in children with UTI and no VUR
(CUTIE) varied from 1 to 2, with a mean CN of 1.69
0.47. A statistically significant number of children
with UTI (n¼ 22; 31%) had one copy of DCHS1 com-
pared to controls (n¼ 3; 0.6%). Individuals with
one copy of DCHS1 compared to all other genotypes
were 73 times more prevalent in the CUTIE cohort
compared to controls (OR¼ 73.03; 95% CI 21.10–
252.76; P< 0.0001). When comparing the two UTI
cohorts, the CUTIE cohort (UTI and no VUR) had
a statistically significant larger percentage of children
with one copy of DCHS1 compared with RIVUR (UTI
and VUR; 31% vs. 7%; OR¼ 5.8 95% CI 3.00–11.19;
P< 0.0001).
DCHS1 protein is expressed in bladder epithelial and
renal intercalated cells
DCHS1’s expression and location in postnatal kidney
and bladder tissue has not been previously described.
Because we discovered a significant genetic variation in
DCHS1 in patients with UTIs, we aimed to localize
DCHS1 protein expression using human tissue. In the
normal human kidney and the kidney from a patient
with pyelonephritis, we demonstrated DCHS1 was
expressed by intercalated cells of renal-collecting duct
epithelia. As many of the innate immune proteins are
expressed in the kidney, DCHS1 localization in inter-
calated cells highlights its likely role in innate immuni-
ty. In the bladder, we demonstrated strong
immunostaining in the bladder epithelia. All tissue
immunostaining is demonstrated in Figure 3.
Dchs1 expression does not significantly increase
in response to murine uropathogen challenge
Following a UPEC challenge in mice (n¼ 15 UTI89,
n¼ 16 CFT073), we quantified the Dchs1 mRNA
amount in both the bladder and kidney (Figure 4).
The cystitis UPEC strain (UTI89) produced a larger
increase in Dchs1 mRNA than the pyelonephritis
UPEC strain did (CFT073). Compared to saline con-
trols, neither kidney nor bladder Dchs1 mRNA tran-
scripts were significantly increased. The bladder
demonstrated the largest increase in UTI89-
challenged mice but missed significance (P¼ 0.11).
Discussion
This study used well-characterized pediatric cohorts
from the previously published RIVUR and CUTIE
studies.19,21 In a genome-wide study focused on a





































Figure 2. DCHS1 DNACNs 1 vs.  2 in subjects with UTI without VUR, UTI with VUR, and controls. Percentage and distribution of
1 CN vs.  2 CN of DCHS1 in subjects with UTI without VUR (n¼ 71), UTI with VUR (n¼ 320), and controls (n¼ 491). CN¼DNA
CN of DCHS1.
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a novel association of DCHS1 relative gene CNV with
UTI, which has not been reported previously.16 In this
report, we determined the absolute DNA CN of
DCHS1 in two clinical cohorts of pediatric UTI to
expand on our genome-wide screening study. We
found that individuals with low DCHS1 CN (one
copy) were 73 times more prevalent in the CUTIE
(UTI without VUR) cohort compared to controls. In
the RIVUR cohort (UTI with VUR), one copy indi-
viduals were 13 times more prevalent. Even in the
absence of VUR, children with UTIs can develop
renal scarring, thus showing that UTI-associated
genes are important for children at risk.21
DCHS1 encodes for atypical cadherin, which
belongs to the cadherin superfamily and is a calcium-
dependent cell–cell adhesion molecule. The encoded
protein has 27 extracellular cadherin repeat domains,
transmembrane domain, and a unique cytoplasmic
region.26 The Dchs1 gene was found to have role in
kidney development in a murine transgenic model.17
Dchs1 also has been shown to have a role in cell adhe-
sion, growth, tissue patterning, and planar cell polari-
ty.18 To the best of our knowledge, the role of DCHS1
in the postnatal kidney has not been investigated.
This report serves as the first study to demonstrate
the association of DCHS1 gene loss in patients with
pediatric UTIs. Our immunostaining demonstrates a
potential postnatal role of DCHS1 in the bladder and
intercalated cells of the kidneys. Many key components
of the innate immune system demonstrate a similar
expression pattern. Thus, this finding supports the
notion that it is critical in innate defenses.25,27
Because Dchs1 expression did not significantly increase
following UPEC challenge, this gene is likely important
in basal defenses and not inducible. Conversely, UPEC
may subvert the epithelial response to invasion,
although our experiments missed this possible role.
Additional murine experiments are needed to dissect
the pathways up- and downstream of DCHS1.
Additionally, transgenic murine studies with bladder
and renal collecting duct deletion will help to determine
which tissue is key in innate defenses and if intercalated
cell dysfunction exists with gene loss.
We can only hypothesize the precise mechanisms of
UTI susceptibility with a single copy of DCHS1, and
further studies are needed. Because DCHS1 is
expressed on the apical surface of epithelia, DCHS1
may have a role in pattern recognition and/or inflam-
matory cascade signaling. Our research group and
others have demonstrated the role of intercalated cells
in the innate defense of the kidney and urinary tract.
Because cell polarity is critical in epithelial cells such as
intercalated cells of the collecting duct, we postulate
that DCHS1 single-copy individuals may have subtle





















Figure 3. Immunolocalization of DCHS1 in human kidney (upper and middle panel) and bladder (lower panel). Upper-left panel:
kidney section showing V-ATPase E1-positive intercalated cell in collecting duct (green, white arrow); middle panel: DCHS1-positive
cells (red, white arrow); and right-panel: merged image (white arrowheads) showing DCHS1-positive intercalated cells. Lower panel:
bladder staining for DCHS1 indicated by arrows; left panel: 10 magnification showing islands of DCHS1 positive infiltrating cells;
middle and right panel: 40 magnification, showing DCHS1-positive bladder urothelium. Blue nucleus staining DAPI, scale bar 50 mm.
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Because we observed the highest percentage of sub-
jects in the UTI cohort without VUR (CUTIE Study
cohort) with a single copy of DCHS1, we postulate that
DCHS1 CNV is more relevant to infection and immu-
nity than abnormal development of the kidney and uri-
nary tract. Additionally, because genetic variations in
DCHS1 were more prevalent in those with normal uri-
nary tracts and an intact anti-reflux anatomy, the
DCHS1 gene is likely more relevant to bladder as
opposed to kidney innate immunity. The gene product
may also prevent attachment in the bladder and/or ure-
thra. Thus, in the context of VUR, bacteria may be
able to ascend the urinary tract to the kidneys quickly,
and the effect of DNA CNVs is blunted if the primary
site of action postnatally is the bladder. If this specu-
lation is true, the association of DNA CNVs in patients
without VUR would be more consistent with the
results of this study.
We do acknowledge some limitations in this study.
First, our study was limited to Caucasian girls. So,
results may not apply to other cohorts. Further inves-
tigations are needed on diverse cohorts to confirm these
findings are consistent across study populations.
Additionally, we utilized an adult cohort of women
for controls. We utilized this cohort for two reasons.
First, large control cohorts of children with no history
of UTI are not publicly available. Second, an adult
control cohort with no history of UTI should actually
have a higher risk of UTI than a pediatric cohort, given
the high incidence of UTI in adult women compared to
children. The impact of this study may need to be tem-
pered until we can perform additional studies to dis-
cover the role of this gene in the postnatal kidney and
urinary tract.
Conclusion
This study represents the first report of DCHS1 in asso-
ciation with UTI. We speculate that the site of biolog-
ical action may be in the lower urinary tract and
“bypassed” to a certain extent in individuals with
VUR. Thus, DCHS1 genetic variations associate with
pediatric UTI risk, but the effect of these variations is



























































































































Figure 4. Dchs1 mRNA expression of murine bladder and kidneys in response to different uropathogenic E. coli strains. A and B
graphs correspond to mRNA upregulation after 6 h on mouse bladder and kidneys infected with UTI89 compared to saline controls
(n¼ 15 UTI89 and n¼ 15 saline). C and D graphs show mRNA transcripts of mouse bladder and kidneys upon inoculation with
CFT073 compared to controls (n¼ 16 CFT073 and n¼ 15 saline), respectively. Long horizontal bars represent the mean, with upper
and lower smaller horizontal bars representing 1 standard deviation.
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body of disease-modifying genes such as DEFA1A3, in
conjunction with patient characteristics such as VUR
grade and bowel/bladder dysfunction to start creating
UTI risk panels for patients at risk for UTI sequelae.13
Further investigation is required to determine the role
of DCHS1 and innate immune functions of the kidney
and urinary tract.
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